Kyorin Pharmaceutical Co (TSE:4569) Tariff Resilience Score: 8/10 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4569 Kyorin Pharmaceutical Co Ltd TSE:4569
74 GF Score
Price 円1,162.00
GF Value 円1,583.07
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Kyorin Pharmaceutical Co Tariff Resilience Score?

Kyorin Pharmaceutical Co TSE:4569 74 Tariff Resilience Score is 8 as of Jul. 21, 2026. GuruFocus rates TSE:4569 with a GF Score™ of 74/100 and a GF Value™ of 円1,583.07 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 1,026 Drug Manufacturers companies, Kyorin Pharmaceutical Co ranks better than 99.61% on this metric.

Kyorin Pharmaceutical Co has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

Kyorin Pharmaceutical Co has Kyorin's primary market is Japan, with limited international exposure, minimizing tariff impact. The pharmaceutical industry often benefits from tariff exemptions, and Kyorin's focus on domestic production further reduces vulnerability.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kyorin Pharmaceutical Co might have Highly Resilient.

Kyorin Pharmaceutical Co  (TSE:4569) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kyorin Pharmaceutical Co Tariff Resilience Score Related Terms

TSE:4569 vs ZTS, UTHR: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyorin Pharmaceutical Co Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's Tariff Resilience Score falls into.


TSE:4569
74GF Score
Kyorin Pharmaceutical Co Ltd TSE:4569
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
Kyorin Pharmaceutical Co (TSE:4569) has a Tariff Resilience Score of 8 as of Jul. 21, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Kyorin Pharmaceutical Co ranks #4 out of 1026 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Kyorin Pharmaceutical Co's Tariff Resilience Score too high?
Kyorin Pharmaceutical Co's current Tariff Resilience Score is 8. Based on the distribution chart, Kyorin Pharmaceutical Co ranks #4 out of 1026 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kyorin Pharmaceutical Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kyorin Pharmaceutical Co's Tariff Resilience Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Kyorin Pharmaceutical Co ranks #4 out of 1026 companies for Tariff Resilience Score. This places Kyorin Pharmaceutical Co in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Kyorin Pharmaceutical Co's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyorin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kyorin Pharmaceutical Co (TSE:4569) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,583.07, compared to a current price of 円1,162.00 — trading 26.6% below its estimated fair value. The current Tariff Resilience Score is 8. Kyorin Pharmaceutical Co's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Kyorin Pharmaceutical Co (TSE:4569), the current Tariff Resilience Score is 8 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyorin Pharmaceutical Co (TSE:4569) Overvalued in 2026?

Based on GuruFocus' analysis, Kyorin Pharmaceutical Co stock appears to be undervalued. The current stock price of 円1,162.00 is trading 26.6% below its estimated GF Value™ of 円1,583.07. GuruFocus considers Kyorin Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4569:

  • Tariff Resilience Score: 8
  • GF Value™: 円1,583.07 vs. price of 円1,162.00 (26.6% below fair value)
  • GF Score™: 74/100 with 6 warning signs

No single metric tells the full story. See the TSE:4569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyorin Pharmaceutical Co Business Description

Address 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.
74GF Score

Get the complete analysis for TSE:4569

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,162.00
Price
円1,583.07
GF Value